An observational study in Crohn's Disease (CD), sponsored by Gazi University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Gazi University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Crohn Disease with a site in Turkey — 10 open to participants now, 20 under way, 15 of them phase 3. Crohn Disease · Turkey.
Among the 55 studies in Crohn Disease with a site in Turkey, this one is one of 9 that started in 2024, is one of 6 observational ones, and was the 55th registered.
1,995 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →10 of the 55 studies in Crohn Disease with a site in Turkey are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Turkey, United States, Argentina and 27 more countries
Ages 18+
Sakarya University · Sites in Turkey
Ages 18+
Janssen Research & Development, LLC · Sites in Turkey, United States, Argentina and 25 more countries
Ages 18+
Eli Lilly and Company · Sites in Turkey, United States, Austria and 19 more countries
Ages 18–70
Janssen Research & Development, LLC · Sites in Turkey, United States, Argentina and 15 more countries
Ages 3+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 1 Month to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 39 · Phase 4 2
First in 2011; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 185 across 645 observational studies indexed under Crohn Disease.
Median enrollment 350 across the 49 interventional studies, 120 across the 6 observational. Of the 33 that completed or were terminated, 24 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 55 have an industry lead sponsor. The 10 most frequent:
Gazi University is the lead sponsor of 552 studies on the registry; 102 are open to participants now.
Gazi University has 3 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Crohn Disease with a site in Turkey that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Crohn Disease with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Crohn's disease (CD) is a chronic inflammatory bowel disease that requires long-term monitoring. Although endoscopy is the gold standard for assessing intestinal inflammation, its invasive nature limits repeated use, particularly in children. Therefore, reliable noninvasive methods are needed to monitor disease activity.
This single-center, prospective observational study aims to evaluate the performance of the Mucosal Inflammation Noninvasive Index (MINI) and the Pediatric Crohn's Disease Activity Index (PCDAI) in children with Crohn's disease.
The study examines the relationship between MINI and PCDAI and evaluates their associations with endoscopic disease activity measured by the Simple Endoscopic Score for Crohn's Disease (SES-CD). It also compares the ability of both indices to identify patients with active intestinal inflammation.
The initial research hypothesis focused on evaluating the correlation between MINI and PCDAI. During the ongoing data collection period, the hypothesis was expanded to investigate whether MINI demonstrates superior discriminative performance compared with PCDAI in identifying endoscopic disease activity as assessed by SES-CD.
Crohn's disease (CD) is a lifelong, chronic inflammatory bowel disease. Endoscopic evaluation is the gold standard for assessing mucosal inflammation; however, it is invasive. This increases the need for reliable noninvasive tools, particularly in pediatric patients. The Mucosal Inflammation Noninvasive Index (MINI) was developed for this purpose. It aims to predict mucosal inflammation by jointly evaluating stool characteristics, fecal calprotectin, erythrocyte sedimentation rate, and C-reactive protein levels. This study has three aims in pediatric patients with CD. The first is to evaluate the relationship between MINI and the Pediatric Crohn's Disease Activity Index (PCDAI). The second is to examine how each index relates to endoscopic disease activity, as determined by the Simple Endoscopic Score for Crohn's Disease (SES-CD), in assessments that include endoscopy. The third is to compare how well the two indices discriminate endoscopically active disease. Ultimately, the study aims to determine whether MINI demonstrates superior performance to PCDAI in discriminating endoscopically active disease in pediatric patients with CD.
This single-center, observational, prospective study was conducted in the Department of Pediatric Gastroenterology at Gazi University Hospital between November 2024 and July 2026. It included patients who had been diagnosed with CD according to the revised Porto/ESPGHAN criteria and were followed up in our department, and met the study eligibility criteria.
**Inclusion Criteria:**
**Exclusion Criteria:**
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Seventy pediatric patients diagnosed with Crohn's disease were included in this prospective observational study. Disease activity was evaluated using MINI and PCDAI, and their relationships with endoscopic activity assessed by SES-CD were investigated.
Correlation Between MINI and PCDAI in Pediatric Crohn's Disease
Time frame: 20 months
Plan to share: Yes
Supporting information: Statistical analysis plan, Informed consent form, Clinical study report
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in Jul 2026, 19 months.
Of 231 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 101. This study's 19 months is below that.
Counting every sponsor, half of 304 studies reached it within 41 months; a quarter within 29 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.